Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 1/20 | 0.48 |
| ▸ | CDK1 | P06493 | 18/20 | 0.44 |
| ▸ | CDK2 | P24941 | 18/20 | 0.44 |
| ▸ | KDR | P35968 | 16/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | CDK4 | P11802 | 2/20 | 0.44 |
| ▸ | CDK7 | P50613 | 2/20 | 0.44 |
| ▸ | CDK9 | P50750 | 2/20 | 0.44 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.44 |
| ▸ | CCND1 | P24385 | 1/20 | 0.44 |
| ▸ | CCNH | P51946 | 1/20 | 0.44 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.43 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4579849 | 0.88 | CDK1 (0.44) | CDK1CDK2KDRCA2CDK4 | |
| SCHEMBL13648651 | 0.84 | CDK2 (0.63) | AURKACDK1CDK2KDRCA2 | |
| SCHEMBL4018345 | 0.81 | AURKA (0.52) | AURKACDK1CDK2KDRCA2 | |
| SCHEMBL5173644 | 0.81 | AURKA (0.52) | AURKACDK1CDK2KDRCA2 | |
| SCHEMBL4580478 | 0.74 | KDR (0.54) | AURKACDK1CDK2KDRCA2 | |
| SCHEMBL4058417 | 0.74 | CDK1 (0.67) | CDK1CDK2KDRCA2CDK4 | |
| SCHEMBL4058428 | 0.74 | CDK1 (0.67) | CDK1CDK2KDRCA2CDK4 | |
| SCHEMBL3931675 | 0.73 | CDK1 (0.56) | CDK1CDK2KDRCA2CDK4 | |
| SCHEMBL4063258 | 0.72 | CDK1 (0.80) | CDK1CDK2KDRCA2CDK4 | |
| SCHEMBL13648442 | 0.72 | CDK2 (0.64) | AURKACDK1CDK2KDRCA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7456191-B2 | N-Aryl-sulfoximine-substituted pyrimidines as CDK-and/or VEGF inhibitors, their production and use as pharmaceutical agents | SCHERING AG (DE) | 2008-11-25 | — | — | US | disclosed |
| US-7456191-B2 | N-Aryl-sulfoximine-substituted pyrimidines as CDK-and/or VEGF inhibitors, their production and use as pharmaceutical agents | SCHERING AG (DE) | 2008-11-25 | — | — | US | disclosed |
| US-20060229325-A1 | N-aryl-sulfoximine-substituted pyrimidines as CDK-and/or VEGF inhibitors, their production and use as pharmaceutical agents | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060229325-A1 | N-aryl-sulfoximine-substituted pyrimidines as CDK-and/or VEGF inhibitors, their production and use as pharmaceutical agents | CDK2, FLT1, CDK4 | AURKA 372/4885CDK1 6/4885CDK2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.